Recombinant Human BGN Protein (C-6His)

Name: Recombinant Human BGN Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0439NP
Availability: InStock

BL-0439NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Biglycan is produced by our Mammalian expression system and the target gene encoding Glu20-Lys368 is expressed with a 6His tag at the C-terminus.
Accession	P21810
Synonym	Biglycan; Bone/Cartilage Proteoglycan I; PG-S1; BGN; SLRR1A
Gene Background	Biglycan is a 200-350 kD proteoglycan consisting of a 45 kD core protein and two chrondroitin/dermatan sulfate glycosaminoglycan chains. Biglycan binds to TGF-ß. It also binds to collagen type I in low ionic strength (less than 3 mM phosphate) buffer. At higher ionic strengths, Biglycan does not bind to collagen type I. It enhances the inhibition effect of TGF-ß on osteoclast proliferation at a concentration of 4-20 mg/ml. It also prevents the attachment of CHO cells to fibronectin, with a 50% inhibition at 17-21 mg/ml.
Molecular Mass	40.47 KDa
Apmol Mass	40-90 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	May be involved in collagen fiber assembly.
Subcellular Location	Secreted, extracellular space, extracellular matrix.
Protein Families	Small leucine-rich proteoglycan (SLRP) family, SLRP class I subfamily
Database References	HGNC: 1044 OMIM: 300106 KEGG: hsa:633 STRING: 9606.ENSP00000327336 UniGene: Hs.821
Associated Diseases	Meester-Loeys syndrome (MRLS); Spondyloepimetaphyseal dysplasia, X-linked (SEMDX)
Tissue Specificity	Found in several connective tissues, especially in articular cartilages.

Gene Functions References

The differential immunoexpression of perlecan and biglycan in these types of ameloblastomas suggests their participation in the developmental process of these tumors. PMID: 29921372
TLR2 and BGN contribute to sterile inflammation and infertility in man. PMID: 27849015
Results show that Biglycan expression was upregulated by DNA demethylation in tumour endothelial cells from myeloma. PMID: 27295191
Elevated biglycan mRNA expression in adipose tissues of obese women PMID: 27465988
sex-specific allele combinations of BGN, COL5A1, and DCN, as well as eight miRNA recognition sequences, were associated with altered susceptibility to anterior cruciate ligament ruptures PMID: 28927971
high Bgn expression levels promote a more dense collagen architecture, leading to increased tissue stiffness. This increased tissue stiffness leads to higher integrin-beta1 expression on melanoma cells, which promotes their invasiveness. PMID: 28476030
The expression of hBGN in the skeletal muscle of the treated mice was 1.34-fold higher than that of the native mouse Bgn (mBgn). The low transduction efficiency and improved motor functions suggest that biglycan expressed in a small number of muscle fibers was likely to have been secreted and anchored to the cell surface throughout the whole muscular fibers PMID: 27485975
Results identified loss-of-function mutation in BGN gene in patients with an X-linked syndromic form of severe thoracic aortic aneurysms and dissections (TAAD) confirming BGN as causative gene in severe form of TAAD. PMID: 27632686
After the first year of smoking abstinence the levels of BGN expression and carotid-femoral pulse wave velocity are significantly improved as compared to baseline. PMID: 28131044
study reports a temporal relationship between altered placental biglycan expression and subsequent development of fetal growth restriction/small for gestational age. PMID: 28408374
Quantitative polymerase chain reaction for messenger RNA expression from tissue specimens revealed significantly higher expression of Biglycan (p = 0.0008) and Lumican (p = 0.01) and lower expression of Decorin (p < 0.0001) in urothelial carcinoma of bladder PMID: 28459201
Mutation in BGN gene is associated with X-Linked Spondyloepimetaphyseal Dysplasia. PMID: 27236923
biglycan exerts an important role in cell proliferation, migration, invasion and apoptosis in colon cancer. PMID: 26459740
BGN might play an important role on metastasis in human endometrial cancer and it might be a target marker for the molecular therapy of advanced and recurrence endometrial cancer. PMID: 26275380
This study demonstrated that the small leucine-rich proteoglycan BGN accumulates in CADASIL and binds to NOTCH3. PMID: 25578324
Biglycan may have a role in development of vascular damage in smokers PMID: 25463076
BGN is a factor secreted by peritubular cells to modulate FGFR3c signaling and thus contributes to the regulation of spermatogonial maintenance PMID: 25260943
The results suggest that regions within BGN is associated with ACL injury susceptibility and that genetic sequence variability within genes encoding proteoglycans may potentially modulate the ligament fibril properties. PMID: 24552666
immunolocalization of decorin and biglycan in samples of first-trimester and term placentas, placenta accreta, invasive mole, and choriocarcinoma PMID: 24117774
Biglycan modulates angiogenesis and bone formation during fracture healing. PMID: 24373744
Data indicate that the biglycan (BGN) CC genotype was significantly over-represented in the control group versus the carpal tunnel syndrome (CTS) group. PMID: 25173489
High expression of BGN in esophageal squamous cell carcinoma indicated aggressive tumor behaviors and predicted a worse clinical outcome. PMID: 24228112
Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. PMID: 24257755
ADAMTS-4 and its substrate biglycan are involved in tubulogenesis by endothelial cells PMID: 24051360
The concentration of aggrecan, biglycan, and decorin was determined in six regions of the human supraspinatus tendon. PMID: 22329809
Molecular haplotypes within the BGN promoter may contribute to the molecular basis of interindividually different transcriptional BGN regulation, possibly modulating the predisposition to cardiovascular disease-related phenotypes. PMID: 23393390
pancreatic adenocarcinoma patients who presented PG-I expression in the extracellular matrix had worse prognosis compared to those who did not PMID: 23007878
Extracellular soluble biglycan induces the expression of BMP-2 and ALP in human aortic valve interstitial cells primarily via TLR2 and contributes to the proosteogenic effect of oxLDL. PMID: 22982459
Up-regulation of biglycan was significantly correlated with poor tumor differentiation, lymph node metastasis, and distant metastasis in colorectal cancer. PMID: 21879307
Bgn inhibits the major properties of HER-2/neu-transformed cells, which is inversely modulated by the PKC signaling cascade. PMID: 22582394
Data show that granzyme B (GrB) liberated TGF-beta1 from substrates decorin, biglycan and betaglycan. PMID: 22479366
These findings suggested that biglycan is a novel tumor endothelial cell marker and a target for anti-angiogenic therapy PMID: 22374465
Biglycan demonstrated distinctive localization relative to nodules within calcified aortic valves. PMID: 21185747
Biglycan enhances ovalbumin-specific cross-priming by over 80% to histocompatibility class I-restricted T cells in both a Toll-like receptor (TLR)2- and TLR4-pathway-dependent manner in transgenic mice. PMID: 22095710
findings demonstrate that Akt is a downstream signalling component of TGF-beta-mediated biglycan core protein synthesis but not glycosaminoglycan chain hyperelongation in vascular smooth muscle PMID: 21913799
Data revealed a strong induction of several genes encoding components of the extracellular matrix, such as collagens, COMP, IGFBP5 and biglycan. PMID: 21029365
This study demonstrates that elevated expression of biglycan may play an important role in the development and progression of gastric cancer, and could be further evaluated as a biomarker for predication of a poor clinical outcome. PMID: 21998129
Immunoprecipitation analysis revealed that biglycan interacts with both the canonical Wnt ligand Wnt3a and the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6), possibly via the formation of a trimeric complex. PMID: 21969569
Biglycan and decorin reduced the proliferation of pre-adipocytes, partly by induction of apoptosis. Furthermore, the anti-proliferative capabilities of decorin and biglycan were nullified with removal of GAG side-chains. PMID: 21702857
Differential expression of 4 out of 5 genes related to estrogen metabolism and action (ESR1, ESR2, PGR and BGN) was confirmed in endometriosis. PMID: 21397694
Biglycan impinges on the expression of total epidermal growth factor receptor and possibly, on the cell-surface expression of the receptors, playing a critical role in the regulation of chondrocyte and pericellular matrix homeostasis. PMID: 20367117
expressed decreased in fetal growth restriction placentae PMID: 20591478
Data show that biglycan (BGN) induces of phospholipid transfer protein (PLTP) in aortic valve interstitial cells via stimulation of Toll-like receptor 2, so increased BGN in stenotic valves contributes to the production of PLTP via TLR 2. PMID: 20382708
study shows (1) a detailed description of ectopic ossification (EO) formed by Bgn, Fmod or combined depletion, (2) the role of exercise in modulating EO and (3) that Bgn and Fmod are critical in controlling motor function. PMID: 19422643
has two GAG chains and affinity to collagen PMID: 11979972
BGN expression is regulated by TGFbeta1 in pancreatic tumor cells and has a role in controlling cell growth PMID: 12140283
isoforms of biglycan have a smaller core protein substituted with smaller glycosaminoglycan chains, are N-glycosylated, which demonstrates that a lack in N-glycosylation is not the reason for a smaller core. PMID: 12153565
biglycan showed a unique ability to organize collagen VI into extensive hexagonal-like networks over a time period of only a few minutes PMID: 12354766
regulation of gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein kinase signaling downstream of Smad signaling PMID: 12538652
Biglycan may be involved in vascular smooth muscle growth & migration through cdk2- & p27-dependent pathways. Changes in its expression may affect arterial susceptibility to vascular injury, & may play a direct role in pathogenesis of vascular lesions. PMID: 15031262

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.